



---

Harnessing the power of T cell measurement

---

January 31, 2014

## **Dr. Peter Wrighton-Smith Named UK BioIndustry Association (BIA) Entrepreneur of the Year**

**OXFORD, UK and MARLBOROUGH, MA, January. 31, 2014** (GLOBE NEWSWIRE) – Oxford Immunotec Global PLC (Nasdaq: OXFD) announced today that its CEO, Dr. Peter Wrighton-Smith has been named the UK BioIndustry Association Entrepreneur of the Year.

“I feel extremely honoured to have received this award, which recognises how far Oxford Immunotec has come from its foundation 11 years ago. The company’s success is the product of the tireless work by our employees, both past and present, and this award belongs as much to them as to me.” said Peter Wrighton-Smith CEO of Oxford Immunotec. “We look forward to continuing that success, and we are proud to be one of the many companies involved in translating the UK’s medical research into commercial success for the UK economy.”

“The BIA Entrepreneur of the Year award was established to recognise an entrepreneur who has achieved a significant level of commercial success and can inspire others dedicated to bioscience endeavours,” said Edward Hodgkin, BIA Chairman. “Peter has led and built Oxford Immunotec from university spin-out to sustainable revenue-generating business – the kind of business that reflects the strength and capabilities of the UK’s bioscience industry.”

-Ends -

## Notes to Editors:

### **About Oxford Immunotec Global PLC**

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. The proprietary T-SPOT® technology platform measures the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. T cells are a central component of the human body's immune system, and are implicated in the control and progression of many medical conditions, including certain types of infectious diseases, cancers and autoimmune diseases. The Company's initial product developed using the T-SPOT technology platform is the T-SPOT. *TB* test, which is used to test for latent tuberculosis infection. The T-SPOT. *TB* test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, UK and in Marlborough, MA. Additional information can be found at [www.oxfordimmunotec.com](http://www.oxfordimmunotec.com).

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

### **About the BioIndustry Association**

Founded 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to [www.bioindustry.org](http://www.bioindustry.org)

### **Forward-Looking Statements**

This release contains forward-looking statements, including statements regarding future success of the company. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

**CONTACTS:**

**For Media Inquiries:**

Caroline Crawley

Oxford Immunotec

Tel: +44 1235 442796

[ccrawley@oxfordimmunotec.com](mailto:ccrawley@oxfordimmunotec.com)

**For Investor Inquiries:**

Rick Altieri

Chief Financial Officer,

Oxford Immunotec

Tel: +1 (508) 481-4648

[raltieri@oxfordimmunotec.com](mailto:raltieri@oxfordimmunotec.com)

Mark Klausner

Westwicke Partners

Tel: +1 (443) 213-0500

[oxfordimmunotec@westwicke.com](mailto:oxfordimmunotec@westwicke.com)

SOURCE: Oxford Immunotec